Tirzepatide, a dual GLP-1 and GIP receptor agonist, has shown powerful results for weight management, but gastrointestinal effects including irritable bowel syndrome (IBS) symptoms occur in a meaningful portion of users
Tm bu faktrler bir araya geldiinde, vcudun serbest radikallere ve toksinlere kar koruma mekanizmas zayflar
The decision to switch medications should always be made collaboratively with your healthcare provider , taking into account your specific cardiovascular condition, blood pressure control, other medical problems, and treatment preferences
Discontinue use and consult a healthcare provider if you experience: Severe allergic reactions (rash, difficulty breathing, swelling), persistent injection site infections, or any concerning symptoms that do not resolve
Related Stories Injectable semaglutide may improve fertility outcomes in PMOS Study links semaglutide and tirzepatide to fewer anxiety and depression diagnoses in obesity care Semaglutide dose may matter more than weight loss for heart health MEPS is a comprehensive, nationally representative, repeated cross-sectional sample of US adults
